SCHEMBL10233308

SCHEMBL10233308

CCOC(=O)C1Cc2cc(Br)ncc2N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.38
MEN1 O00255 4/20 0.38
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 3/20 0.38
MAPK1 P28482 2/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14401106 0.90 KMT2A (0.40) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL1769713 0.86 KMT2A (0.38) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL29878652 0.86 KMT2A (0.38) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL13889991 0.85 KMT2A (0.38) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL862757 0.79 MEN1 (0.49) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL29803501 0.78 KDM4E (0.43) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL22462285 0.78 KDM4E (0.43) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL2608545 0.76 NAMPT (0.43) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL10256197 0.76 MEN1 (0.41) KMT2AMEN1KDM4EHSD17B10ALDH1A1
SCHEMBL10906291 0.76 KDM4E (0.53) KMT2AMEN1KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158622-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2012-04-17 US disclosed
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2009-01-22 US disclosed
US-7405210-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase OSI PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE BRADLEY STUART E 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE PYGL, PYGM, PYGB KMT2A 2476/4885MEN1 4163/4885KDM4E 2422/4885
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PYGL, PYGM, PYGB KMT2A 2476/4885MEN1 4163/4885KDM4E 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.